Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 18 studies | 47% ± 17% | |
lung | 16 studies | 38% ± 14% | |
intestine | 13 studies | 31% ± 15% | |
kidney | 9 studies | 32% ± 13% | |
liver | 6 studies | 27% ± 10% | |
placenta | 5 studies | 27% ± 16% | |
bone marrow | 5 studies | 32% ± 15% | |
pancreas | 4 studies | 47% ± 19% | |
lymph node | 4 studies | 40% ± 6% | |
brain | 4 studies | 30% ± 9% | |
uterus | 3 studies | 39% ± 13% | |
adrenal gland | 3 studies | 29% ± 14% | |
prostate | 3 studies | 23% ± 5% | |
breast | 3 studies | 27% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 3822.97 | 1445 / 1445 | 100% | 57.73 | 183 / 183 |
intestine | 100% | 7057.38 | 966 / 966 | 100% | 99.84 | 527 / 527 |
liver | 100% | 3075.10 | 226 / 226 | 100% | 46.31 | 406 / 406 |
ovary | 100% | 3493.37 | 180 / 180 | 100% | 51.00 | 430 / 430 |
skin | 100% | 3784.67 | 1809 / 1809 | 100% | 49.73 | 472 / 472 |
stomach | 100% | 5627.62 | 359 / 359 | 100% | 84.07 | 286 / 286 |
kidney | 100% | 11499.66 | 89 / 89 | 100% | 79.16 | 900 / 901 |
thymus | 100% | 4415.61 | 653 / 653 | 100% | 65.41 | 604 / 605 |
bladder | 100% | 4443.10 | 21 / 21 | 100% | 74.66 | 503 / 504 |
prostate | 100% | 4471.92 | 245 / 245 | 100% | 50.37 | 501 / 502 |
uterus | 100% | 3172.28 | 170 / 170 | 100% | 58.59 | 458 / 459 |
lung | 100% | 5227.69 | 578 / 578 | 100% | 61.11 | 1151 / 1155 |
brain | 99% | 3011.36 | 2625 / 2642 | 100% | 35.86 | 704 / 705 |
breast | 100% | 4415.07 | 459 / 459 | 99% | 69.03 | 1108 / 1118 |
pancreas | 99% | 2243.55 | 324 / 328 | 100% | 78.56 | 178 / 178 |
adrenal gland | 100% | 5978.06 | 258 / 258 | 99% | 45.41 | 227 / 230 |
adipose | 100% | 4349.47 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 44.35 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 140.00 | 29 / 29 |
peripheral blood | 100% | 16013.78 | 929 / 929 | 0% | 0 | 0 / 0 |
spleen | 100% | 7053.46 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 44.95 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 34.43 | 1 / 1 |
blood vessel | 100% | 4077.93 | 1333 / 1335 | 0% | 0 | 0 / 0 |
heart | 95% | 2063.96 | 815 / 861 | 0% | 0 | 0 / 0 |
muscle | 93% | 2287.82 | 748 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005515 | Molecular function | protein binding |
Gene name | PRR13 |
Protein name | Proline-rich protein 13 (Taxane-resistance protein) Proline rich 13 |
Synonyms | BM-041 TXR1 |
Description | FUNCTION: Negatively regulates TSP1 expression at the level of transcription. This down-regulation was shown to reduce taxane-induced apoptosis. . |
Accessions | ENST00000549135.1 [Q9NZ81-1] F8VP70 ENST00000549581.5 [Q9NZ81-2] F8VRX0 F8VZP4 Q9NZ81 ENST00000547368.5 ENST00000549068.5 F8W1R5 ENST00000549924.5 [Q9NZ81-1] ENST00000551945.5 ENST00000379786.8 [Q9NZ81-2] F8VWB5 F8VU40 ENST00000551003.5 ENST00000429243.7 [Q9NZ81-1] ENST00000546581.5 ENST00000549740.5 |